Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Royalty Pharma plc - Class A Ordinary Shares (NQ:RPRX)

55.36 -0.71 (-1.27%)
Streaming Delayed Price Updated: 1:33 PM EDT, Jul 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Royalty Pharma plc - Class A Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Branded Pharmaceuticals Stocks Q1 Recap: Benchmarking Royalty Pharma (NASDAQ:RPRX)
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Royalty Pharma (N... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Unpopular Stocks We’re Skeptical Of
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cord... 
Via StockStory
News headline image
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q1 Earnings?
Royalty Pharma has been on fire lately. In the past six months alone, the company’s stock price has rocketed 46.3%, reaching $55.73 per share. This performan... 
Via StockStory
Topics Supply Chain
News headline image
Mattel Stock Is Down 24%. Here's What a $50.9 Million Exit Could Mean ↗
Mattel is a global toy and entertainment company behind brands like Barbie, Hot Wheels, and Fisher-Price, serving families worldwide. 
Via The Motley Fool
Topics Regulatory Compliance
Royalty Pharma (NASDAQ:RPRX) Beats Q1 Estimates and Raises Guidance, Fueling Strong Momentum ↗
Via Chartmill
Royalty Pharma PLC (NASDAQ:RPRX) Emerges as a Compelling Value Investment ↗
Via Chartmill
ROYALTY PHARMA PLC-CL A (NASDAQ:RPRX) Shows High Technical and Setup Ratings Ahead of Potential Breakout ↗
Via Chartmill
News headline image
Royalty Pharma’s Q1 Earnings Call: Our Top 5 Analyst Questions
Royalty Pharma’s first quarter results surpassed Wall Street’s revenue and adjusted EBITDA expectations, driven by robust growth across its diversified royal... 
Via StockStory
Topics Earnings
News headline image
Why One Fund’s $4 Million Centerra Gold Exit Looks Like Profit-Taking Amid a 150% Rally ↗
Centerra Gold operates integrated mining projects in North America and Turkey, generating revenue from gold, copper, and molybdenum sales. 
Via The Motley Fool
News headline image
This Fund Cashed Out of Preformed Line Products Amid a 150% Stock Surge ↗
Preformed Line Products designs and manufactures network hardware for utilities and telecoms across global infrastructure markets. 
Via The Motley Fool
Topics Regulatory Compliance Supply Chain
Royalty Pharma PLC-CL A (NASDAQ:RPRX) Shares Dip Despite Strong Portfolio Growth and 2026 Guidance Beat ↗
Via Chartmill
Why Is TEVA Stock Rising Pre-Market Today? ↗
Via Stocktwits
News headline image
Royalty Pharma (RPRX) Q1 2026 Earnings Transcript ↗
Royalty Pharma (RPRX) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Royalty Pharma (RPRX) Reports Q1: Everything You Need To Know Ahead Of Earnings
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting earnings this Wednesday before market hours. Here’s what investors should know. R... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Unpopular Stocks We’re Skeptical Of
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
News headline image
1 Healthcare Stock with Promising Prospects and 2 Facing Headwinds
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali... 
Via StockStory
News headline image
Branded Pharmaceuticals Stocks Q4 Teardown: Royalty Pharma (NASDAQ:RPRX) Vs The Rest
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking a... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
1 Value Stock for Long-Term Investors and 2 Facing Challenges
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether t... 
Via StockStory
News headline image
1 Cash-Producing Stock to Own for Decades and 2 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
Topics Energy
News headline image
The Brain Barrier Broken: Inside Denali Therapeutics’ Landmark FDA Approval of AVLAYAH
On March 25, 2026, the landscape of neurodegenerative medicine underwent a seismic shift. The U.S. Food and Drug Administration (FDA) granted accelerated approval to Denali Therapeutics (NASDAQ: DNLI)... 
Via Finterra
Topics Economy Initial Public Offering
News headline image
Royalty Pharma (RPRX): Buy, Sell, or Hold Post Q4 Earnings?
Royalty Pharma has had an impressive run over the past six months. While the S&P 500 has been flat, the stock has returned 31.5% and now trades at $45.91. Th... 
Via StockStory
Topics Artificial Intelligence Stocks Supply Chain
News headline image
3 Healthcare Stocks Walking a Fine Line
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare... 
Via StockStory
Topics Stocks
News headline image
5 Insightful Analyst Questions From Royalty Pharma’s Q4 Earnings Call
Royalty Pharma’s fourth quarter results did not meet Wall Street’s revenue or earnings expectations, with management attributing the performance to a combination of gradual product transitions in key... 
Via StockStory
Topics Earnings
News headline image
Patient Capital Bet Heavily on Chime Financial (CHYM) With a 2.04 Million Share Purchase ↗
Chime Financial delivers digital-first, fee-free banking solutions for U.S. consumers seeking accessible, low-cost financial services. 
Via The Motley Fool
News headline image
Royalty Pharma (RPRX) Q4 2025 Earnings Transcript ↗
Royalty Pharma (RPRX) Q4 2025 Earnings Transcript 
Via The Motley Fool
Topics Bonds
News headline image
Royalty Pharma (NASDAQ:RPRX) Reports Sales Below Analyst Estimates In Q4 CY2025 Earnings
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) fell short of the market’s revenue expectations in Q4 CY2025 as sales rose 4.7% year on year to $622 million. Its GAAP profit of $0.64 per... 
Via StockStory
News headline image
What To Expect From Royalty Pharma’s (RPRX) Q4 Earnings
Healthcare royalties company Royalty Pharma (NASDAQ:RPRX) will be reporting results this Wednesday morning. Here’s what to expect. 
Via StockStory
Topics World Trade
News headline image
3 Mid-Cap Stocks We Keep Off Our Radar
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract... 
Via StockStory
News headline image
3 Profitable Stocks with Open Questions
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
News headline image
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Royalty Pharma (NASDAQ:RPRX)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how branded pharmaceuticals stocks fared in Q3, starting with... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.